Skip to main content
Free trial

Ask AI to review this stock

Copy the prompt to get recent events, historical reactions, and a short research brief.

Tell your AI:

Help me set up FinLab and analyze 6569 醫揚. Please read: https://finlab.finance/en/setup?stock=6569

No install, open FinLab Studio

6569

醫揚 Biotech & Healthcare As of 2026-06-17 Updated daily after market close

steady quality, fair valuation.

1 active signal
Revenue ≥20%
This page refreshes daily after the close. Add 醫揚 to your watchlist to track signal changes on your next visit.
Valuation 42Quality 58Growth 84Momentum 56Chips 63

Is 醫揚 a buy? Fundamentals and valuation first

  • Above-average profitability.Operating margin is in the 55th market percentile. Latest quarterly ROE ≈ 2.5%.

  • Valuation is neutral.PE is in the 62th market percentile; within its own history, PE is around the 84th percentile.

  • Foreign investors are net buying.Foreign 20-day net flow ≈ 2.1% of volume (net buy).

  • Strong revenue growth.Latest monthly revenue YoY ≈ 49.8%, above the 20% growth threshold.

  • Signals are active now.On the latest data, signals such as Revenue YoY ≥ 20% are active — see the historical forward returns after each occurrence below.

Chip flow

Bullish +0.44
BearishNeutralBullish

Institutional rotation, concentration steady — bullish

  • Institutional rotation, concentration steady — bullish
  • 凱基-信義 holds 102 lots
  • sellers have 210 lots left, ~30 sessions to clear

Window from 2026-01-17 · Price +5% · branches to 2026-06-17· TDCC to 2026-06-12

  • Largest holder 凱基-信義 has accumulated 102 lots since the start (sold 0%), still adding.
  • Main distributor 凱基-站前 peaked at 151 lots, has sold 59%, 62 left, paused recently.
  • TDCC big holders (absolute) >1000-lot holders +0.00pp, mid holders +2, retail -2.18pp — little change.
  • Foreign hedge-desk net short Net short -52 lots (inferred from branch profile, mostly hedging — not necessarily bearish, not case-confirmed).
Branch inventory reconstruction
Accumulating holders Branches that accumulated shares during the window and still hold positive inventory; they are the absorbing side.
Distributing sellers Branches that built inventory earlier and have been selling it down; the remaining number estimates what has not cleared.
Net-short desks Trading-desk branches with negative inventory or net selling, often hedge, offsetting, or short-term flow. It is not automatically a bearish view.
Accumulating
凱基-信義新光摩根大通台灣摩根士丹利永豐金-南投臺銀
Distributing
凱基-站前元大-新莊永豐金-板盛陽信兆豐-嘉義富邦-敦南
Desks
own scale
元大證券兆豐-高雄富邦-陽明永全-南崁
Price Accumulating & Distributing share one scale (comparable); Desks is independent. Zero is the baseline
Branch details Unit: lots

Accumulating

  • 凱基-信義 +102
    sold 0%· still adding
  • 新光 +81
    sold 0%· still adding
  • 摩根大通 +59
    sold 0%· still adding
  • 台灣摩根士丹利 +39
    sold 0%· still adding
  • 永豐金-南投 +38
    sold 0%
  • 臺銀 +35
    sold 3%· still adding

Distributing

  • 凱基-站前 62 left
    sold 59%· paused recently
  • 元大-新莊 42 left
    sold 54%· ~8 sessions to clear
  • 永豐金-板盛 58 left
    sold 26%· ~29 sessions to clear
  • 陽信 46 left
    sold 30%· paused recently
  • 兆豐-嘉義 29 left
    sold 51%· ~15 sessions to clear
  • 富邦-敦南 14 left
    sold 73%· ~16 sessions to clear

Desks

  • 元大證券 -443
    unclassified
  • 兆豐-高雄 -198
    unclassified
  • 富邦-陽明 -83
    unclassified
  • 永全-南崁 -66
    unclassified
Still selling 210 lots ~30 sessions to bottom at most
Recent buy/sell force +555 absorbed / -196 sold buyers slightly ahead
TDCC big holders · absolute-holding cross-check
>1000-lot holder share Retail (<400 lots) share Price (right axis)

Mixed direction: big-holder and retail changes are not aligned.

Describes chip flow, not investment advice. Branch data discloses only high-volume branches with ~1-day lag; TDCC is weekly. Inventory is a relative reconstruction from the window start, not absolute holdings.

Historical evidence

Signals active now

These signals are true on the latest data, with this stock's own historical forward-return stats after each occurrence.

Monthly revenue YoY ≥ 20% (from filing deadline)

Active · now 49.78%

Monthly revenue YoY ≥ 20%; event date is the first trading day after the filing deadline (no look-ahead).

42 historical occurrences (since 2016-12-21)
Average forward return after Monthly revenue YoY ≥ 20% (from filing deadline)。20-day: Win 55.6%, Sample 36, Median +0.48%, Excess -0.56%, Beat mkt rate 38.9%；60-day: Win 54.3%, Sample 35, Median +1.58%, Excess -1.21%, Beat mkt rate 54.3%；120-day: Win 45.7%, Sample 35, Median -0.61%, Excess -9.42%, Beat mkt rate 31.4%

120 days after: historical avg +0.48%

20-day +1.56%
60-day +2.12%
120-day +0.48%
20-day
60-day
120-day
Win
55.6%
54.3%
45.7%
Sample
36
35
35
Median
+0.48%
+1.58%
-0.61%
Excess
-0.56%
-1.21%
-9.42%
Beat mkt rate
38.9%
54.3%
31.4%

Over 35 occurrences, 120-day forward avg gained 0.48%, lagged the market by 9.42 pts; win rate 45.7%.

Valuation regime and subsequent returns

Each day's PE is converted to its own-history percentile (as of that day), then we look at adjusted-close returns over the next 240 trading days by valuation regime.

PE percentile bandSample days240-day avg returnMedianWin rateAvg excess (vs index)
0-20 29Insufficient data
20-40 278+55.7% +60.6% 98.2% +22.4%
40-60 283+2.5% -3.8% 36.4% -16.4%
60-80 406+0.6% -5.3% 38.4% -20.1%
80-100 You are here325-19.7% -22.3% 8.6% -46.5%

Percentiles use an expanding own-history window (no look-ahead); forward return is 240 trading days on adjusted close. Sample days overlap; distribution is indicative only.

Current PE ≈ 30.73, at the 84.1th percentile of its own history (80-100 band).

Valuation × momentum historical grid

Every day in its own history is bucketed by valuation tercile (own-history PE) and 60-day momentum sign into six cells; we show adjusted-close returns over the next 120 trading days per cell.

Valuation
Momentum
Cheap (own-history bottom 1/3)
Mid
Expensive (own-history top 1/3)
60-day momentum up
+50.6%
Win rate 88.7% Excess +33.5%
142d
+6.3%
Win rate 50.4% Excess -9%
240d
Now
-11.9%
Win rate 14.3% Excess -23.6%
343d
60-day momentum down
+23.9%
Win rate 100% Excess +8.6%
73d
+7.5%
Win rate 56% Excess -4%
268d
-6.6%
Win rate 25.6% Excess -19.2%
363d

Currently in “Expensive (own-history top 1/3) × 60-day momentum up”: across 343 historical days, 120-day forward avg declined 11.9%, win rate 14.3%, lagged the market by 23.6%.

Days = trading days in this bucket; returns use adjusted prices, ex-costs. 60-day momentum: direction of this stock's price over the past 60 trading days.

Does this signal hold up across the market

Over the past 242 months, on average ~404 stocks per month met “monthly revenue YoY ≥ 20%”; their adjusted-close return over the next 60 trading days averaged 6.94% (equal-weighted), beating the market by 2.37 points on average, and outperformed the TAIEX total-return index in 64.5% of months.

Each month, equal-weighted 60-day forward adjusted return of all signal-matching stocks, then averaged across months; excess vs the TAIEX total-return index.

Signals not active (historical stats for reference)

These are not occurring now; historical samples shown for comparison.

252-day price high (breakout)

Pending

Adjusted close makes a new 252-day high; repeats within 20 days counted once.

6 times historically; 60-day forward avg +16.61%, win rate 83.3%, beating the market by +13.89 pts on average.

Foreign net buying for 5 straight days

Pending

Foreign net flow (ex-dealer) positive for 5 straight days; event on day 5; repeats within 20 days counted once.

22 times historically; 60-day forward avg -0.64%, win rate 42.9%, beating the market by -8.29 pts on average.

What does 醫揚 do? Company profile

生技醫療業；醫療用工業電腦、智慧醫療硬體與醫療設備OEM/ODM 上櫃

Overview

6569 對應證券為醫揚科技股份有限公司，英文名 Onyx Healthcare Inc.，為櫃買中心上櫃普通股，非 ETF、ETN、權證或特別股。公司成立於 2010/02/02，為研揚科技旗下醫療用工業電腦公司，上櫃日期為 2016/12/21，總部/登記地址為新北市新店區寶橋路235巷135號4樓，主要生產據點位於新店。董事長為莊永順，總經理為莊富鈞，發言人為陳盈德。公開股市資料顯示資本額約新台幣3.9至3.91億元；員工規模未能在本次可查來源中完整確認，Goodinfo揭露2025年度全體員工平均薪資為103.2萬元/人，但未揭露員工人數。主要股東方面，研揚科技股份有限公司為核心大股東，公開持股資料顯示約持有18,694,156股、約47.85%至47.92%；莊永順及其關係法人瑞海投資亦為重要經營/董事持股來源。2025年股東常會改選第六屆董事，董事包含瑞海投資代表人莊永順、莊富鈞，以及研揚科技代表人賴立凱、薛紹周。

Business

醫揚主要從事醫療用電腦設計、製造及銷售，以及其他零組件買賣。主要產品包括醫療用電腦及配件、生理監測系統、行動醫療輔具、行動護理系統、醫療控制器、長照照護系統、醫療電源、ODM/OEM服務等。MoneyDJ資料顯示2024年銷售產品比重中，醫療用電腦及配件約佔98%；銷售地區以外銷為主，2024年外銷約佔99%、內銷約佔1%，外銷以歐美為最大宗。公司以 Onyx 品牌銷售，也提供 ODM/OEM。商業模式可分為兩大類：一是智慧醫療IT設備，銷售醫療級電腦、行動護理與長照終端等硬體平台；二是全球醫療儀器OEM/ODM，協助醫療儀器、檢驗設備、AI醫療設備客戶進行硬體設計、認證、製造與長週期供貨。2025年新聞指出醫揚全球醫療儀器OEM與智慧醫療IT設備營收占比約各半，主要OEM業務在美洲，智慧醫療IT設備約90%在歐洲；但公司正推動美洲醫療IT通路與歐洲OEM專案互補。重要應用包含醫院資訊終端、手術室/診間AI影像運算、AI內視鏡、血液分析儀、行動護理、智慧長照、醫療伺服器與邊緣AI平台。

Outlook 2025–2028

2025至2028年展望重點在醫療AI、歐美市場互補、醫療設備代工與長照應用。2024年疫情期間遞延需求消退，全年營收約12.42億元、年減約16.85%，但毛利率約35.9%仍持穩；公司因歐盟醫療法規由MDD轉向MDR而投入重新認證，短期費用率壓力較高，但若認證通過，將提高歐洲醫療市場進入門檻與產品生命週期保護。2024年第四季公司取得衛福部QMS/GMP證書，有利於拓展醫療設備代工，案例包括血液分析儀與AI智慧內視鏡。2025年公司主軸為醫療AI 2.0，推廣高算力AI醫療伺服器平台，切入智慧醫院、AI醫療流程、影像判讀與手術導航等應用。2026年Q1法說資訊顯示醫療AI裝置客製代工被管理層視為第三成長引擎，AI手術導航、AI內視鏡即時判讀、Holosuite數位孿生、手術機器人等應用陸續由PoC進入design-in與量產；公司稱已開發超過30種醫療AI相關產品，並同步佈局NVIDIA Jetson、Blackwell、IGX與Intel Core Ultra/NPU平台。區域策略方面，歐洲維持醫院通路並取得7至10年期OEM/ODM專案，美洲由代工延伸到醫療IT通路，日本因智慧長照補助與東京營運據點帶動營收占比提升。風險包括：醫療產品認證時程與費用、MDR/QMS/GMP法規門檻、少數專案出貨波動、醫療設備採購週期長、CPU/GPU/記憶體漲價與交期拉長造成存貨與現金流壓力、匯率波動、歐美醫院資本支出延後、醫療AI軟硬體量產速度不如預期，以及與大型醫療設備廠/AI軟體商合作時議價能力受限。2027至2028年的具體財務目標未見公司明確公開揭露，本段對2027至2028年的判斷屬基於醫療AI專案量產、長約OEM/ODM及智慧長照趨勢的研究推估。

Supply Chain

Upstream
  • 研揚科技股份有限公司 6579 母公司與核心大股東，屬工業電腦平台與集團資源來源；公開資料顯示研揚持有醫揚約47.85%至47.92%，董事會亦有研揚代表人。
  • 英特爾 Intel 非台股公司；醫揚醫療電腦、行動護理與邊緣AI平台使用Intel處理器/Core Ultra/NPU等運算平台，屬關鍵上游晶片與平台生態系。
  • 輝達 NVIDIA 美國上市公司、非台股；醫揚醫療AI伺服器與邊緣AI產品導入NVIDIA GPU、Jetson、Blackwell、IGX等平台，並提及為NVIDIA GPU醫療AI生態系一環。
  • 友達光電股份有限公司 2409 台股上市面板廠；醫揚重要原物料包含液晶顯示器與觸控螢幕，友達為台灣主要面板供應商之一，但本次未查得醫揚明確指定供應商名單，屬產業鏈可能供應來源。
  • 群創光電股份有限公司 3481 台股上市面板廠；醫揚產品需液晶顯示器/觸控面板，群創為台灣主要面板供應商之一，但未確認為醫揚直接供應商。
  • 記憶體、板卡、金屬機殼、觸控螢幕與作業系統供應商 MoneyDJ揭露醫揚主要原物料包含板卡、液晶顯示器、金屬機殼、觸控螢幕、記憶卡/模組及作業系統；個別供應商名稱未公開確認。
Downstream
  • 全球醫療儀器設備大廠 多為海外或未具名客戶；醫揚在醫療儀器設備方向主要作為硬體供應商/OEM/ODM夥伴，搭配客戶軟體、應用與品牌進入全球市場。
  • 歐美醫院與醫療IT通路商 醫揚智慧醫療IT設備以歐洲市場為大宗，並積極開拓美洲醫療IT通路；客戶多未公開揭露，可能包含醫療院所、系統整合商與通路商。
  • 醫療AI軟體公司與AI醫療方案商 醫揚提供醫療AI伺服器、邊緣AI平台與醫療級硬體，配合AI內視鏡、手術導航、檢驗設備與長照應用；具名客戶未公開。
  • 日本智慧長照與照護應用通路/機構 公司因應日本智慧長照補助與東京營運據點，發展智慧長照、行動照護與照護平台相關需求；具體客戶未公開。

Competitors

Sources（12）

This company profile is compiled from public sources (annual reports, filings, news and analyst reports), not finlab backtest data; the 2025–2028 outlook contains forward-looking estimates and is for reference only.

Method and limitations

  • All returns use adjusted close (etl:adj_close), already adjusted for dividends and splits.
  • Excess return is measured against the TAIEX total-return index (dividends included).
  • Valuation regime and percentile stats use an expanding own-history window (no future data).
  • Revenue-signal event dates align to the first trading day after the filing deadline, avoiding look-ahead.
  • Event samples may overlap in time; stats describe historical distribution only and are less reliable when samples are few.

This page is historical statistics for educational purposes and is not investment advice. Investing involves risk; past performance does not indicate future results. Assess and bear the risk yourself before trading.